Insider · CIK 0001571820

Chanda Sanjay

Reports to the SEC for 2 companies · MENLO PARK, CA

sec.gov

Transactions

Companies

Filings

CIK

0001571820

Forms 4 and 5

Insider transactions

43 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-03-19	ANTXAN2 Therapeutics, Inc. · Stock Option (right to buy)A Award	Chief Development Officer	AAward	+66K sh	—	—	66,000
2026-03-19	ANTXAN2 Therapeutics, Inc. · Stock Option (right to buy)D Disposition to Issuer	Chief Development Officer	DDisposition to Issuer	−66K sh	—	—	0
2026-03-19	ANTXAN2 Therapeutics, Inc. · Stock Option (right to buy)A Award	Chief Development Officer	AAward	+58K sh	—	—	57,950
2026-03-19	ANTXAN2 Therapeutics, Inc. · Stock Option (right to buy)D Disposition to Issuer	Chief Development Officer	DDisposition to Issuer	−58K sh	—	—	0
2026-03-19	ANTXAN2 Therapeutics, Inc. · Stock Option (right to buy)A Award	Chief Development Officer	AAward	+41.7K sh	—	—	41,665
2026-03-19	ANTXAN2 Therapeutics, Inc. · Stock Option (right to buy)D Disposition to Issuer	Chief Development Officer	DDisposition to Issuer	−41.7K sh	—	—	0
2026-02-20	ANTXAN2 Therapeutics, Inc.A Award	Chief Development Officer	AAward	+38K sh	—	—	118,823
2026-02-20	ANTXAN2 Therapeutics, Inc. · Stock Option (right to buy)A Award	Chief Development Officer	AAward	+77K sh	—	—	77,000
2026-01-06	ANTXAN2 Therapeutics, Inc.S Sale	Chief Development Officer	SSale	−5,956 sh	$1.01	−$6,027.472	75,823
2026-01-05	ANTXAN2 Therapeutics, Inc.S Sale	Chief Development Officer	SSale	−3,295 sh	$1.00	−$3,304.885	81,779
2025-02-26	ANTXAN2 Therapeutics, Inc.A Award	Chief Development Officer	AAward	+50.3K sh	—	—	80,074
2025-02-26	ANTXAN2 Therapeutics, Inc. · Stock Option (right to buy)A Award	Chief Development Officer	AAward	+101K sh	—	—	100,500
2025-01-03	ANTXAN2 Therapeutics, Inc.S Sale	Chief Development Officer	SSale	−2,957 sh	$1.34	−$3,965.337	29,824
2024-03-15	ANTXAN2 Therapeutics, Inc.A Award	Chief Development Officer	AAward	+27.5K sh	—	—	28,235
2024-03-15	ANTXAN2 Therapeutics, Inc.A Award	Chief Development Officer	AAward	+27.5K sh	—	—	28,235
2024-03-15	ANTXAN2 Therapeutics, Inc. · Stock Option (right to buy)A Award	Chief Development Officer	AAward	+55K sh	—	—	55,000
2023-02-15	ANTXAN2 Therapeutics, Inc. · Stock Option (right to buy)A Award	Chief Development Officer	AAward	+58K sh	—	—	57,950
2022-05-12	ANTXAN2 Therapeutics, Inc. · Stock Option (right to buy)A Award	Chief Development Officer	AAward	+66K sh	—	—	66,000
2015-03-04	Anacor Pharmaceuticals, Inc.M Exercise/Conversion	SVP, Drug Development	MExercise/Conversion	+4,952 sh	$7.25	+$35.9K	34,039
2015-03-04	Anacor Pharmaceuticals, Inc.S Sale	SVP, Drug Development	SSale	−4,952 sh	$45.00	−$223K	29,087
2015-03-04	Anacor Pharmaceuticals, Inc.M Exercise/Conversion	SVP, Drug Development	MExercise/Conversion	+48 sh	$7.55	+$362.4	29,135
2015-03-04	Anacor Pharmaceuticals, Inc.S Sale	SVP, Drug Development	SSale	−48 sh	$45.00	−$2,160	29,087
2015-03-04	Anacor Pharmaceuticals, Inc.Stock Option (right to buy)M Exercise/Conversion	SVP, Drug Development	MExercise/Conversion	−4,952 sh	$7.25	−$35.9K	0
2015-03-04	Anacor Pharmaceuticals, Inc.Stock Option (right to buy)M Exercise/Conversion	SVP, Drug Development	MExercise/Conversion	−48 sh	$7.55	−$362.4	13,552
2015-02-03	Anacor Pharmaceuticals, Inc.A Award	SVP, Drug Development	AAward	+5,020 sh	—	—	29,087
2015-02-03	Anacor Pharmaceuticals, Inc.Stock Option (right to buy)A Award	SVP, Drug Development	AAward	+20.8K sh	—	—	20,845
2015-02-03	Anacor Pharmaceuticals, Inc.Performance Restricted Stock UnitsA Award	SVP, Drug Development	AAward	+1,475 sh	—	—	1,475
2014-12-19	Anacor Pharmaceuticals, Inc.M Exercise/Conversion	SVP, Drug Development	MExercise/Conversion	+7,011 sh	$6.92	+$48.5K	11,006
2014-12-19	Anacor Pharmaceuticals, Inc.M Exercise/Conversion	SVP, Drug Development	MExercise/Conversion	+12.1K sh	$5.59	+$67.4K	23,068
2014-12-19	Anacor Pharmaceuticals, Inc.Stock Option (right to buy)M Exercise/Conversion	SVP, Drug Development	MExercise/Conversion	−7,011 sh	$6.92	−$48.5K	18,489
2014-12-19	Anacor Pharmaceuticals, Inc.Stock Option (right to buy)M Exercise/Conversion	SVP, Drug Development	MExercise/Conversion	−12.1K sh	$5.59	−$67.4K	14,938
2014-11-26	Anacor Pharmaceuticals, Inc.M Exercise/Conversion	SVP, Drug Development	MExercise/Conversion	+5,000 sh	$7.25	+$36.3K	8,995
2014-11-26	Anacor Pharmaceuticals, Inc.S Sale	SVP, Drug Development	SSale	−5,000 sh	$35.00	−$175K	3,995
2014-11-26	Anacor Pharmaceuticals, Inc.Stock Option (right to buy)M Exercise/Conversion	SVP, Drug Development	MExercise/Conversion	−5,000 sh	$7.25	−$36.3K	4,952
2014-09-10	Anacor Pharmaceuticals, Inc.M Exercise/Conversion	SVP, Drug Development	MExercise/Conversion	+5,047 sh	$7.25	+$36.6K	9,042
2014-09-10	Anacor Pharmaceuticals, Inc.S Sale	SVP, Drug Development	SSale	−5,047 sh	$24.25	−$122K	3,995
2014-09-10	Anacor Pharmaceuticals, Inc.M Exercise/Conversion	SVP, Drug Development	MExercise/Conversion	+4,953 sh	$5.00	+$24.8K	8,948
2014-09-10	Anacor Pharmaceuticals, Inc.S Sale	SVP, Drug Development	SSale	−4,953 sh	$24.25	−$120K	3,995
2014-09-10	Anacor Pharmaceuticals, Inc.Stock Option (right to buy)M Exercise/Conversion	SVP, Drug Development	MExercise/Conversion	−5,047 sh	$7.25	−$36.6K	9,952
2014-09-10	Anacor Pharmaceuticals, Inc.Stock Option (right to buy)M Exercise/Conversion	SVP, Drug Development	MExercise/Conversion	−4,953 sh	$5.00	−$24.8K	0
2014-02-07	Anacor Pharmaceuticals, Inc.Stock Option (right to buy)A Award	SVP, Drug Development	AAward	+47K sh	—	—	47,000
2013-11-07	Anacor Pharmaceuticals, Inc.Stock Option (right to buy)A Award	SVP, Drug Development	AAward	+30K sh	—	—	30,000
2013-04-12	Anacor Pharmaceuticals, Inc.Stock Option (right to buy)A Award	SVP, Drug Development	AAward	+60K sh	—	—	60,000

Recent filings

Accepted (ET)
Mar 234
Chanda Sanjay0001193125-26-120235
SEC(opens sec.gov)
Feb 234
Chanda Sanjay0001193125-26-064141
SEC(opens sec.gov)
Jan 74
Chanda Sanjay0001193125-26-006765
SEC(opens sec.gov)
Feb 284
Chanda Sanjay0000950170-25-030057
SEC(opens sec.gov)
Jan 74
Chanda Sanjay0000950170-25-003157
SEC(opens sec.gov)
Mar 294/A
Chanda Sanjay0001610717-24-000192
SEC(opens sec.gov)
Mar 184
Chanda Sanjay0001610717-24-000166
SEC(opens sec.gov)
Feb 174
Chanda Sanjay0000899243-23-005557
SEC(opens sec.gov)
May 164
Chanda Sanjay0000899243-22-018296
SEC(opens sec.gov)
Mar 44
Anacor Pharmaceuticals, Inc.0001209191-15-022578
SEC(opens sec.gov)

Companies

Address

C/O AN2 THERAPEUTICS, INC. 1300 EL CAMINO REAL, SUITE 100

MENLO PARK, CA, 94025